BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function.
Saved in:
| Title: | BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function. |
|---|---|
| Authors: | Pour L; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. Electronic address: pour.ludek@fnbrno.cz., Delimpasi S; Department of Haematology, Evangelismos Hospital, Athens, Greece., Legiec W; Department of Hematology and Bone Marrow Transplantation, St. John of Dukla Oncology Center, and Institute of Medical Science, Faculty of Medicine, The John Paul II Catholic University of Lublin, Poland., Minarik J; Department of Hemato-Oncology, University Hospital Olomouc, Olomouc, Czech Republic., Spicka I; First Department of Medicine - Department of Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic., Grosicki S; Department of Cancer Prevention, Medical University of Silesia, Katowice, Poland., Rymko M; Department of Bone Marrow Transplantation and Hematologic Oncology, Nasz Lekarz Medical Outpatient Clinics Slawomir Jeka, Toruń, Poland., Najda J; Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland., Symeonidis A; Department of Internal Medicine, University of Patras, Patras, Greece., Andersson B; Oncopeptides AB, Stockholm, Sweden., Huledal G; Oncopeptides AB, Stockholm, Sweden., Norin S; Oncopeptides AB, Stockholm, Sweden., Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Medicine, Korea University, Seoul, South Korea. |
| Source: | Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2026 Jul; Vol. 26 (7), pp. e942-e952. Date of Electronic Publication: 2026 Apr 30. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Multicenter Study |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42215355 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Pour+L%22">Pour L</searchLink>; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. Electronic address: pour.ludek@fnbrno.cz.<br /><searchLink fieldCode="AU" term="%22Delimpasi+S%22">Delimpasi S</searchLink>; Department of Haematology, Evangelismos Hospital, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Legiec+W%22">Legiec W</searchLink>; Department of Hematology and Bone Marrow Transplantation, St. John of Dukla Oncology Center, and Institute of Medical Science, Faculty of Medicine, The John Paul II Catholic University of Lublin, Poland.<br /><searchLink fieldCode="AU" term="%22Minarik+J%22">Minarik J</searchLink>; Department of Hemato-Oncology, University Hospital Olomouc, Olomouc, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Spicka+I%22">Spicka I</searchLink>; First Department of Medicine - Department of Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Grosicki+S%22">Grosicki S</searchLink>; Department of Cancer Prevention, Medical University of Silesia, Katowice, Poland.<br /><searchLink fieldCode="AU" term="%22Rymko+M%22">Rymko M</searchLink>; Department of Bone Marrow Transplantation and Hematologic Oncology, Nasz Lekarz Medical Outpatient Clinics Slawomir Jeka, Toruń, Poland.<br /><searchLink fieldCode="AU" term="%22Najda+J%22">Najda J</searchLink>; Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.<br /><searchLink fieldCode="AU" term="%22Symeonidis+A%22">Symeonidis A</searchLink>; Department of Internal Medicine, University of Patras, Patras, Greece.<br /><searchLink fieldCode="AU" term="%22Andersson+B%22">Andersson B</searchLink>; Oncopeptides AB, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Huledal+G%22">Huledal G</searchLink>; Oncopeptides AB, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Norin+S%22">Norin S</searchLink>; Oncopeptides AB, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Dimopoulos+MA%22">Dimopoulos MA</searchLink>; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Medicine, Korea University, Seoul, South Korea. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101525386%22">Clinical lymphoma, myeloma & leukemia</searchLink> [Clin Lymphoma Myeloma Leuk] 2026 Jul; Vol. 26 (7), pp. e942-e952. <i>Date of Electronic Publication: </i>2026 Apr 30. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase II; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101525386 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2152-2669 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221522669%22">21522669 </searchLink><i>NLM ISO Abbreviation: </i>Clin Lymphoma Myeloma Leuk <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42215355 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.clml.2026.04.022 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e942 Titles: – TitleFull: BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Pour L – PersonEntity: Name: NameFull: Delimpasi S – PersonEntity: Name: NameFull: Legiec W – PersonEntity: Name: NameFull: Minarik J – PersonEntity: Name: NameFull: Spicka I – PersonEntity: Name: NameFull: Grosicki S – PersonEntity: Name: NameFull: Rymko M – PersonEntity: Name: NameFull: Najda J – PersonEntity: Name: NameFull: Symeonidis A – PersonEntity: Name: NameFull: Andersson B – PersonEntity: Name: NameFull: Huledal G – PersonEntity: Name: NameFull: Norin S – PersonEntity: Name: NameFull: Dimopoulos MA IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 07 Text: 2026 Jul Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 2152-2669 Numbering: – Type: volume Value: 26 – Type: issue Value: 7 Titles: – TitleFull: Clinical lymphoma, myeloma & leukemia Type: main |
| ResultId | 1 |
